MGTX - MeiraGTx Holdings plc
| Previous Close | 13.16 |
| Open | 12.57 |
| Bid | 8.80 x 1000 |
| Ask | 31.03 x 1000 |
| Day's Range | 11.41 - 12.61 |
| 52 Week Range | 8.82 - 30.23 |
| Volume | 113,087 |
| Avg. Volume | 125,690 |
| Market Cap | 429.297M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.65 |
| Earnings Date | Mar 10, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 35.25 |
- Zacks
Abeona Treats First Patient in Pivotal Gene Therapy Study
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
- GlobeNewswire
MeiraGTx Reports Full Year 2019 Financial Results
LONDON and NEW YORK, March 11, 2020 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.
- GlobeNewswire
MeiraGTx Announces Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) Designations Granted by the European Medicines Agency to AAV-RPGR Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosa
LONDON and NEW YORK, March 02, 2020 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) and Advanced Therapy Medicinal Product (ATMP) designations to AAV-RPGR, MeiraGTx’s investigational gene therapy for the treatment of x-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene. MeiraGTx and Janssen Pharmaceuticals, Inc. (Janssen), part of the Janssen Pharmaceutical Companies of Johnson & Johnson, are jointly developing AAV-RPGR as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases.
- GlobeNewswire
MeiraGTx to Present at Upcoming Investor Conferences
LONDON and NEW YORK, Feb. 24, 2020 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria.
- Simply Wall St.
Should You Take Comfort From Insider Transactions At MeiraGTx Holdings plc (NASDAQ:MGTX)?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- Zacks
What Makes MeiraGTx Holdings PLC (MGTX) a Strong Momentum Stock: Buy Now?
Does MeiraGTx Holdings PLC (MGTX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks
5 Biotech Stocks Set for Continued Rally in 2020
The advance in gene therapy and RNA interference has boosted the biotech space so far in 2019. With the projected growth in the sector, here are five stocks poised to grow.
- Insider Monkey
Hedge Funds Have Never Been This Bullish On MeiraGTx Holdings plc (MGTX)
Is MeiraGTx Holdings plc (NASDAQ:MGTX) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
- GlobeNewswire
MeiraGTx to Host Parkinson’s Disease R&D Day in New York
LONDON and NEW YORK, Dec. 05, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a Parkinson’s disease-focused R&D Day on December 13, 2019 from 9:00-11:30 a.m. ET in New York. The program will focus on MeiraGTx’s investigational gene therapy candidate AAV-GAD in development for the treatment of Parkinson’s disease. MeiraGTx’s president and CEO, Alexandria Forbes, Ph.D., will be joined by additional members of the senior leadership team, in addition to leading clinicians and researchers, to discuss the current Parkinson’s disease treatment landscape and results from Phase 1 and Phase 2 clinical trials of AAV-GAD.
- Zacks
Gene Therapy the Next Best Thing: Here's Why (Revised)
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
- Zacks
Gene Therapy the Next Best Thing: Here's Why
Recent activities like mergers and collaboration have boosted the gene therapy space this year, the broad and intriguing pipelines shows that the segment is poised to grow.
- GlobeNewswire
MeiraGTx to Present at Upcoming Healthcare Conferences
LONDON and NEW YORK, Nov. 26, 2019 -- MeiraGTx Holdings plc (NASDAQ:MGTX), a vertically integrated, clinical stage gene therapy company, today announced.
- Simply Wall St.
Can You Imagine How MeiraGTx Holdings's (NASDAQ:MGTX) Shareholders Feel About The 21% Share Price Increase?
It hasn't been the best quarter for MeiraGTx Holdings plc (NASDAQ:MGTX) shareholders, since the share price has fallen...
- GlobeNewswire
MeiraGTx Reports Third Quarter 2019 Financial Results
LONDON and NEW YORK, Nov. 07, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.
- Insider Monkey
Is MeiraGTx Holdings plc (MGTX) Going to Burn These Hedge Funds?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
- GlobeNewswire
MeiraGTx to Present at Upcoming Scientific and Investor Conferences
LONDON and NEW YORK, Oct. 03, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that the Company will.
- GlobeNewswire
MeiraGTx To Present Clinical Data from Phase 1/2 Trial of AAV-RPE65 at Upcoming Scientific Conferences
MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that clinical data updates from the Company’s Phase 1/2 trial of AAV-RPE65 will be presented at two upcoming medical meetings. The Phase 1/2 open-label, multi-center, dose-finding trial evaluated AAV-RPE65 in patients with retinal dystrophy associated with disease-causing variants in the RPE65 gene, a condition that causes severe sight impairment beginning at birth. AAV-RPE65 is a second-generation gene therapy candidate developed specifically to treat RPE65-deficiency, and optimized for transduction efficiency, potency and stability.
- Simply Wall St.
Could MeiraGTx Holdings plc's (NASDAQ:MGTX) Investor Composition Influence The Stock Price?
Every investor in MeiraGTx Holdings plc (NASDAQ:MGTX) should be aware of the most powerful shareholder groups...
- GlobeNewswire
MeiraGTx Announces Pricing of Public Offering of Ordinary Shares
LONDON and NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced the pricing of an underwritten public offering of 3,200,000 of its ordinary shares at a public offering price of $23.50 per share. In addition, MeiraGTx has granted the underwriters a 30-day option to purchase up to an additional 480,000 of its ordinary shares at the public offering price, less underwriting discounts and commissions. BofA Merrill Lynch, Piper Jaffray and Chardan are acting as joint book-running managers of the offering.
- GlobeNewswire
MeiraGTx Announces Proposed Public Offering of Ordinary Shares
LONDON and NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has commenced an underwritten public offering of $75 million of its ordinary shares. In connection with the offering, MeiraGTx intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ordinary shares sold in the public offering. All of the ordinary shares are being offered by MeiraGTx.
- GlobeNewswire
MeiraGTx Reports Second Quarter 2019 Financial Results and Provides Corporate Update
LONDON and NEW YORK, Aug. 07, 2019 -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial.
- Motley Fool
Why McEwen Mining, MeiraGTx Holdings, and Electronic Arts Slumped Today
Find out why these stocks had significant drops.
- Motley Fool
3 Small-Cap Biotech Stocks That Soared Last Week
It was a great week for these three stocks, but can they continue climbing?
- Simply Wall St.
Estimating The Intrinsic Value Of MeiraGTx Holdings plc (NASDAQ:MGTX)
How far off is MeiraGTx Holdings plc (NASDAQ:MGTX) from its intrinsic value? Using the most recent financial data...
- Motley Fool
3 Biotech Stocks That Soared Last Week: Are They Buys?
Can these high-flying biotech stocks keep the momentum going?
